Skip to content
DataLookout
Menu

AERODUO-2NCT07896252

Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Minor Start date changed from estimate of Oct 2026 to Nov 1, 2026
    • Site details revised at 1 of 2 sites
  2. Notable Recruitment opened
    • Study sites: 0 to 2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Bronchodilation - FEV1
Timeframe: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Bronchodilation - FEV AUC
Timeframe: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Bronchodilation - Peak FEV1
Timeframe: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Bronchodilation - time to onset of FEV1 >100mL
Timeframe: Change in FEV1 >100mL from pre-dose on Days 1 and 14

Secondary (9)

Pharmacokinetics - Cmax
Pharmacokinetics - AUC
Pharmacokinetics - Tmax
Treatment-emergent adverse events (TEAEs)
Blood Pressure
Show 4 moreShow less
Heart Rate
12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)
Clinical laboratory - Hematology
Clinical laboratory - Blood Chemistry

Arms and interventions

AERO-001 low doseExperimental
AERO-001 medium doseExperimental
AERO-001 high doseExperimental
AERO-002 low doseExperimental
AERO-002 medium doseExperimental
AERO-002 high doseExperimental
AERO-007Experimental
PlaceboPlacebo comparator

Drugs: AERO-001, AERO-002, AERO-007

Sites

2 sites in 1 country